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Highly purified intravenous immunoglobulin G concentrate (IV IgG) was produced with the use of 
polyethylene glycol associated to a single-stage precipitation by ethanol, instead of the classic Cohn-
Oncley process, which employs cold alcohol as the precipitating agent, in a three-stage process. 
Precipitation of crude fraction containing more than 95% of immunoglobulin G was performed by 
liquid chromatography with a cation exchanger, CM-Sepharose, as a stationary phase. During the 
process, the product was subjected to two-stage viral inactivation. The first stage was performed by 
the action of sodium caprylate, 30 mM at pH 5.1+/- 0.1, and the second stage was performed by the 
action of a solvent-detergent mixture. The finished product was formulated at 5% with 10% sucralose 
as the stabilizing agent. The process yields 3.3g of IgG/liter of plasma. The finished product analysis 
showed an anti-complementary activity lower than 1CH50. Polymer and aggregate percent levels were 
lower than 3% in the five batches studied. The analysis of neutralizing capacity showed the presence of 
antibacterial and antiviral antibodies in at least three times higher concentrations than the levels found 
in source plasma. The finished product fulfilled all purity requirements stated in the 4th edition of the 
European pharmacopeia.
Uniterms: Blood derivatives. Immunoglobulins. Polyethylene glycol. Ultrafiltration. Ion exchange 
chromatography.
Obteve-se concentrado de imunoglobulina G intravenosa IgGIV, altamente purificado, utilizando-se 
polietilenoglicol associado a uma única etapa de precipitação por etanol, em substituição ao tradicional 
método descrito por Cohn-Oncley, que emprega, em três etapas, o mesmo álcool resfriado, como 
agente precipitante. A purificação da fração bruta contendo mais de 95% de imunoglobulina G foi 
realizada utilizando-se cromatografia líquida com um trocador de cátion, a CM-Sepharose, como fase 
estacionária. Durante o processamento o produto foi submetido a dupla inativação viral sendo a primeira 
pela ação do caprilato de sódio, 30 mM a pH 5,1+/- 0,1 e a segunda por ação de mistura de solvente/
detergente. O produto acabado foi formulado a 5% utilizando-se sucralose 10% como estabilizante. O 
rendimento da metodologia foi de 3,3g de IgG/litro de plasma. A análise do produto acabado demonstrou 
atividade anti-complementar inferior a 1CH50. O valor percentual de polímeros e agregados em cinco 
lotes realizados foi inferior a 3%. O estudo da capacidade de neutralização demonstrou a presença de 
anticorpos anti-bacterianos e anti-virais em concentração pelo menos três vezes maior que o plasma de 
origem. O produto acabado apresentou conformidade com todos os requisitos de pureza dispostos na 
farmacopéia européia IV edição.
Unitermos: Hemoderivados. Imunoglobulinas. Polietilenoglicol. Ultrafiltração. Cromatografia de troca 
iônica. 
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INTRODUCTION
Blood derivatives are biologic medicines produced 
from industrial fractionation of human plasma, and sub-
jected to industrialization and normatization processes that 
confer quality, stability, activity, and specificity (RDC 46, 
2003). Among these products, intravenous immunoglobu-
lin G concentrates, IV IgG, play a prominent role, with a 
growing world demand in the last decade due to their new 
therapeutic applications (Lloret, 2008). This demand is 
expected to reach 100 tons by 2012 (Robert, 2006).
Martha (2004) carried out a literature review of the 
history of immunoglobulin replacement therapy since 
the discovery of antibody capacity to neutralize antigens, 
described by Kitasato in 1890, up to the present day. The 
therapeutic advantage of intact molecules from IV IgG 
concentrates has also been reported in comparison to en-
zymatically modified products (Berger, 2008).
The first papers reporting the production of concen-
trates containing intact molecules were published in the 
1990s. A methodology of IV IgG production, fully deve-
loped by liquid chromatography, has also been described 
(Tanaka, 1998). Although liquid chromatography pro-
cesses have an established role in the protein purification 
industry, precipitation techniques for primary isolation of 
biological material continue to attract the interest of rese-
archers, mainly because of their low cost (Chang, 2000; 
Buchacher, 2006).
Indeed, chemical agents capable of altering plasma 
protein solubility, without causing their denaturation, have 
been frequently used in research laboratories for the pu-
rification of small quantities of proteins. (Lebing, 2003). 
Polyols, particularly polyethylene glycol (PEG), have for 
many years attracted the interest of the blood derivative 
industry. Curling (1980) presented a plasma fractionation 
method using polyethylene glycol as a precipitating agent. 
Curling concluded that PEG presented considerable advan-
tages of use compared to ethanol, and may shortly be widely 
used in the production of blood derivatives. Polyethylene 
glycol has recently been employed in human plasma frac-
tionation for the production of a crude fraction of immuno-
globulin which was kept in a solution, and then treated with 
two-stage ion exchange chromatography (Teschner, 2007).
Octanoic acid is another precipitating agent frequen-
tly used in the purification of biological products. Chanutin 
and Curnish (1960) assessed the inherent characteristics of 
short-chain fatty acids (C6 – C12) for plasma protein preci-
pitation in an acid medium. The authors concluded that, 
among the compounds tested, caprylic acid (C8) presented 
higher precipitation efficiency. They also concluded that 
gamma globulins induced less precipitation than alpha-
globulins and beta-globulins. This paper was a starting 
point for the development of several other IgG purification 
methods, using caprylic acid as a primary stage in the 
production of immunoglobulins G.
Lebing and cols. (2003) reported the production of 
a highly purified concentrate, associating precipitation 
by caprylic acid with other purification processes. Con-
taminant proteins were extracted with caprylic acid 20 
mM in acid pH, placing the IgGs in solution, which were 
then subjected to double ion exchange chromatography 
after clarification, the first with a cation exchanger, and 
the second with an anion exchanger (Lebing et al., 2003).
In view of the evidence found in the literature and 
the need to establish new technologies for the production 
of blood derivatives in Brazil, the aim of the present paper 
was to develop an alternative methodology to the classic 
method of cold ethanol, for the production of a solution 
containing immunoglobulin G concentrate. In order to 
achieve this goal, a combination of two non-denaturing 
chemical agents (caprylic acid and polyethylene glycol) 
was tested in the precipitation of protein fractions. Deter-
gent action of caprylic acid, described by Lundblad, (1991) 
was also assessed in the inactivation of enveloped viruses.
MATERIALS AND METHODS
Arithmetic mean values from results of the analy-
sis of the quality parameters within three experimental 
batches were computed. All techniques employed during 
purity assays for the product in process and for the finished 
product are according to the Pharmacopeia. The Biuret 
method was used in protein content determination during 
process control, while the Kjeldahl method was employed 
for the finished product. Purity of the concentrates obtai-
ned was assessed by agarose gel electrophoresis according 
to the guidelines of the European Pharmacopeia (EP). 
Molecular integrity was assessed by HPLC with 600 x 
75 mm columns, according to EP monograph (2.2.29 EP 
monograph, 5th edition). IgA and IgM quantification was 
performed by ELISA (enzyme-linked immunosorbent 
assay). Anti-complementary activity was determined ac-
cording to its specific monograph (2.6.17 EP monograph, 
5th edition). The ELISA test for the finished product was 
non-reactive during the study of antibodies screened for 
blood donation, such as anti-HIV1 and anti-HIV2, and 
also antibodies against hepatitis B surface antigens. The 
presence of antibacterial antibodies was detected by he-
magglutination. The presence of antiviral antibodies not 
screened in the blood center was also detected by ELISA 
test. Figure 1 shows all steps for purification and prepara-
tion of immunoglobulin concentrates.
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Production of immunoglobulin G (IgG) crude 
paste
The starting material was fresh frozen plasma (FFP), 
which was thawed at + 4 °C and then clarified by centrifu-
gation at 12,000 rpm. The cryoprecipitate paste recovered 
was discarded, and supernatant was treated. The first pre-
cipitation was obtained by pH adjustment to 4.1± 0.1, with 
acetic acid 0.5M and the addition of polyethylene glycol 
q.s.p 6% m/v. After 6 hours under slow homogenization, 
the precipitate was separated by centrifugation. Super-
natant pH was adjusted to 7.5 ± 0.1, and polyethylene 
glycol q.s.p. 12% m/v was added. Some immunoglobulin 
G-rich crude paste was obtained and separated by centri-
fugation.
1st Viral inactivation and production of IgG pure 
paste
IgG crude paste was dissolved in water for injection 
into a quantity equivalent to six times its weight (kg/L), 
and its pH was adjusted to 5.1 ± 0.1. Caprylic acid q.s.p. 
30 mM was then added. The suspension was kept under 
constant agitation at 25 ºC ± 1 ºC for 1 hour, as the first 
viral inactivation step (Lundblad, 1991). Polyethylene 
glycol q.s.p. 3% m/v was added, with the formation of a 
precipitate, which was discarded by centrifugation. Super-
natant was filtered, and a hyaline solution was obtained. 
Its pH was adjusted to 7.3 ± 0.1, and then temperature 
was lowered to close to 0 ºC, and the addition of ethanol 
q.s.p. 25% was begun. The increase in alcohol concentra-
tion took place concomitantly with suspension cooling, 
such that the product in process temperature was close 
to – 5 ºC at the end of ethanol addition. After reaching 
optimum cold temperature, between - 5 ºC and -7 ºC, im-
munoglobulin precipitation started, and took 8 hours. The 
precipitate formed, made up of pure IgG, was recovered 
by centrifugation.
2nd Viral inactivation, chromatographic 
purification and formulation
IgG pure paste was dissolved in water for injection 
into a quantity equivalent to six times its weight (kg/L), 
and its pH was adjusted to 4.5 ± 0.2 with HCL 0.5 N, and a 
clarifying filtration was performed with absolute porosity 
values of 0.65µm. A limpid solution was obtained. 
In order to reduce ionic force, IgG solution was 
diafiltered with water for injection into a quantity equiva-
lent to twice its dissolution volume, followed by protein 
concentration adjustment to 5%. Diafiltration and protein 
level adjustment were performed using a 30 KD Millipore 
Pellicon System.
The solution with low ionic force was subjected to a 
viral inactivation process by action of a solvent-detergent 
mixture with Tri-n-butyl phosphate 0.3% (m/m) and Twe-
en 80 1% (m/m) at 25 °C (Horowitz, 1992).
A final purification process was performed by ion 
exchange liquid chromatography with CM Sepharose 
FF as stationary phase. The system was balanced by four 
FIGURE 1 - Flow chart showing purification and production of IV IgG 5% used in the present study.
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volumes of NaCl 0.02 M buffer pH 4.0. The sample was 
injected at 1.5 times the column volume in each cycle. 
Solvent-detergent mixture elimination was performed by 
washing of stationary phase with ten times the column 
volume of glycine buffer solution 0.01 M at pH 7.0. IgG 
was eluted with seven volumes of glycine buffer solution 
0.1 M plus NaCl 0.15 M at pH 9.0
Eluate pH was adjusted to 4.1–4.3 with hydrochloric 
acid buffer solution 0.1M, and diafiltration was performed 
against 3 volumes of sucralose buffer solution 10%. Pro-
tein levels were adjusted to 5%. The Millipore Pellicon 
System was used again, with cutting power of 10KD. 
The solution was filtered by sterilizing filters and then 
packaged aseptically.
RESULTS AND DISCUSSION
The traditional use of methods that employ etha-
nol in all plasma fractionation steps can be justified by 
several specific features such as low molecular weight, 
reduced volatility when cooled, known bacteriostatic 
property, and recovery possibility due to redistillation. 
Polyethylene glycol (PEG), however, has a very pro-
minent feature related to preservation of IgG molecular 
structure: it has no denaturizing action against IgG. In 
order to reach a synergic result, two types of alcohol 
were used in the present study: PEG was used for crude 
purification, and ethanol was used in the last step of the 
process. IgG crude fraction had 95% purity, while the 
gamma fraction in the finished product was 100% pure. 
IgG subclasses were distributed identically to human 
plasma, and the concentrate obtained was potentially 
effective for use in any situation requiring direct neutra-
lization of antigens, including placental barrier transpo-
sition (Grey, 1964). Other gamma-globulins such as IgM 
and IgA, with molecular weight close to IgG, were not 
detected. The latter was considered by the authors as the 
possible culprit for anaphylactic reactions related to the 
use of immunoglobulins. (Ullmann, 1989)
The methodology presented here can be used in 
factory-scale production, because it can be linked to other 
technologies, with no loss in the recovery of coagulation 
factors and albumin. The average yield of the technique 
was 3.3 grams of pure IgG for each liter of fractionated 
plasma.
Inclusion of an ethanol precipitation step in the im-
munoglobulin separation showed advantages in relation 
to the elimination of precipitating agent by ultrafiltra-
tion. Ultrafiltration flow was higher in the PEG-ethanol 
combined technique (45 l/hour) compared to purification 
technique using polyethylene glycol only (32 L/hour). The 
introduction of an ethanol precipitation step in the 25% 
final concentration also brings advantages to the combined 
process, because it is considered a step in viral reduction 
(Morgenthaler, 1989).
Two viral inactivation processes were introduced 
into the methodology, both using validated techniques. 
The first was the action of caprylic acid 30 mM at pH 5.1, 
which has a detergent action on the lipid membrane of en-
veloped virus. (Parkinnen, 2007). The second methodolo-
gy for viral inactivation was the action of polysorbate and 
tri-butyl phosphate (solvent/detergent) mixture, which also 
acts on viral lipid envelope. There is also the possibility of 
introducing a viral reduction step by nanofiltration, aimed 
at eliminating non-enveloped virus such as parvovirus B19 
and HVA (Kreil, 2006).
Complementary activity measurements show that 
the finished product could be injected by intravenous 
infusion without any undue activation of the complement 
system (US FDA 2008). The absence of aggregates due to 
purification by polyethylene glycol lends stability to the 
molecule, with no need for treatment with enzymes and/or 
acids that would change molecular structure. The limpid 
solution obtained reflects this stability. When quantified, 
the percentage area of the chromatogram corresponding 
to the aggregates was 0.5% (Figure 2).
After being subjected to 57°C for 50 hours, no chan-
ges were observed in the physical features of the solution 
compared to the same solution not subjected to these 
temperatures for 50 hours. Purity of IV IgG solution was 
confirmed by gel electrophoresis, when starting plasma 
was compared to the obtained solution (Figure 3).
 Plasma 
The ELISA test for the finished product was non-
reactive during the search for antibodies screened for 
blood donation, such as anti-HIV1 and anti-HIV2, and 
also antibodies against hepatitis B surface antigens. The 
presence of antibacterial antibodies was detected by 
hemagglutination. The presence of antiviral antibodies 
not screened in the blood center was also detected by the 
ELISA test. Considering that the starting plasma used in 
the process was collected from a dengue endemic zone 
(Cordeiro, 2007), anti-dengue IgG high titers were detec-
ted in the finished product (average optic density [OD] 35, 
positive for OD>10). The present study should be extended 
in order to identify the presence of more than one viral 
subtype in IgG concentrate, which could potentially cause 
ADE (antibody dependent enhancement) phenomenon if 
the product were indicated for dengue cases (Figueiredo, 
1999). The results are displayed in Table I.
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FIGURE 2 - Chromatogram showing the absence of aggregates and a monomer area main peak of 99.5%.
FIGURE 3 - Electrophoresis of fresh plasma sample (left) and 
of the finished product (IgG 5%). 
CONCLUSION
The technology developed by the authors of the pre-
sent paper showed high yield levels in the production of 
intact IgG – 3.3g/liter of plasma. The method has potential 
to offer higher productivity than the Cohn-Oncley method, 
because the precipitation time of the fractions obtained 
by ethanol is higher than in the fractions obtained using 
polyethylene glycol. It also enables introduction of seve-
ral parallel technologies in order to improve the finished 
product purification process, and also allows linking of 
this method to other plasma fractionation methodologies. 
It is important to emphasize that thermal stability at 57 °C 
for 54 hours allows the development of another viral 
inactivation step. The method described here can certainly 
help fractionation centers to develop, or improve, their 
techniques for production of IV IgG concentrates, with 
intact molecules and preserved subclasses, increasing the 
range of indications and also enhancing the chances of 
therapeutic success.
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TABLE I - Biochemical/Immunological Characterization of 5%. IgG IV solution
Immunobiochemical Characterization
Analysis* Normal values Result
Protein Conc. 50 mg/mL ± 10% 52 mg/mL
Protein Content (pureness)
Subclass distribution 
IgG1
IgG2
IgG3
IgG4
Minimum of 95% IgG
Percent
65 – 70
20 – 25
7 – 10
3 – 6
Minimum of 100% IgG
Percent
64
22
8
6
pH 4.0 - 7.4 4.52
IgA - Not detectable 
IgM - Not detectable
Anti-complementary (CH50)
Anti-HIV1 antibodies
Anti-HIV2 antibodies
Anti-HBSAg antibodies 
≤ 1 
Absent
Absent
Absent
≤ 1
Absent
Absent
Absent
Anti-Streptococcus antibodies - Present
Anti-parvovirus antibodies - Present
Anti-rubella antibodies - Present
Anti-dengue antibodies - Present
Quantification of aggregates ≤ 3% 0.5%
Stability at 57 °C/4 h No gellification No gellification
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